Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TERT | O14746 | 3/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14142562 | 1.00 | L3MBTL1 (0.47) | L3MBTL1POLBTERTSPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL2674867 | 0.98 | L3MBTL1 (0.46) | L3MBTL1POLBTERTSPHK2SPHK1 | |
| SCHEMBL28983612 | 0.84 | LTA4H (0.49) | L3MBTL1POLBTERTSPHK2SPHK1 | |
| SCHEMBL28983613 | 0.84 | LTA4H (0.49) | L3MBTL1POLBTERTSPHK2SPHK1 | |
| SCHEMBL7764760 | 0.81 | POLB (0.50) | L3MBTL1POLBTERTSPHK2SPHK1 | |
| SCHEMBL2155920 | 0.81 | POLB (0.50) | L3MBTL1POLBTERTSPHK2SPHK1 | |
| SCHEMBL10002487 | 0.81 | POLB (0.50) | L3MBTL1POLBTERTSPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL2674244 | 0.80 | POLB (0.48) | L3MBTL1POLBTERTSPHK2SPHK1 | |
| SCHEMBL4259281 | 0.79 | TERT (0.50) | L3MBTL1TERT | |
| SCHEMBL28570207 | 0.78 | L3MBTL1 (0.47) | L3MBTL1POLBTERTLTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912988-B1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2014-04-16 | — | — | EP | claimed |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | claimed |
| EP-1912988-A1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-04-23 | — | — | EP | claimed |
| WO-2007017577-A1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-02-15 | — | — | WO | claimed |
| US-7662824-B2 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| WO-2006101937-A1 | ACYLHYDRAZONES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066610-A1 | Acylhydrazones as kinase modulators | MET, ERBB2, ERBB3 | L3MBTL1 1588/4885POLB 4309/4885TERT 1668/4885 |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | PRMT7, PRKACA, PRKX | L3MBTL1 4682/4885POLB 1761/4885TERT 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.